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Aim: PD-L1 expression and high levels of microsatellite instability (MSI-H) may predict response
to checkpoint inhibitors, but their prevalence and prognostic value are unknown in many can-
cers. Methods: We retrospectively evaluated PD-L1 combined positive score (CPS) and MSI-H and
their association with clinical outcomes among patients with ten advanced uncommon cancers.
Results: 398 of 426 patients (93%) had a valid PD-L1 result; most (242; 61%) had CPS ≥1. Prevalence of
MSI-H tumors was 8/360. Median overall survival was shorter among patients with PD-L1 CPS ≥1 tumors
after first-line treatment (23.0 vs 39.7 months, p = 0.014). Conclusion: PD-L1 was commonly expressed in
solid tumors, and CPS ≥1 was associated with shorter overall survival. Prevalence of MSI-H was low.
Lay abstract: Certain biologic characteristics of tumors (or biomarkers) may be used to assess the likely
course of a patient’s disease (i.e., their prognosis) and/or how they may respond to treatment. We eval-
uated whether the presence of the protein PD-L1 and high levels of microsatellite instability were asso-
ciated with overall survival among patients with ten uncommon advanced cancers. PD-L1 was commonly
expressed in solid tumors and its presence may be associated with shorter overall survival. Prevalence of
high microsatellite instability was low.
First draft submitted: 9 April 2020; Accepted for publication: 22 June 2020; Published online:
19 August 2020
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The advent of immunotherapies targeting the PD-1 pathway has improved outcomes for patients with certain
advanced solid tumors [1]. Checkpoint inhibitors targeting the PD-1/PD-L1 immune checkpoint pathway block
the interaction between PD-1 and its ligands, PD-L1 and PD-L2, and have demonstrated durable antitumor
response and manageable toxicity among patients with a variety of solid tumor types [2–5]. PD-L1 is an immune
checkpoint protein commonly expressed on tumor cells that interacts with PD-1 on T-cells and other immune
cells, thereby inhibiting T-cell proliferation, cytokine production and cytotoxic activity [3,6]. Additionally, tumor
cells may have defects in DNA mismatch repair (dMMR), which typically result in hundreds to thousands of
somatic mutations, microsatellite instability (MSI) and presentation of potential neoantigens [7]. Tumors with high
levels of MSI (MSI-H) upregulate immune checkpoint proteins, including PD-L1, enabling evasion of immune
surveillance [8,9]. As response to anti-PD-1 therapies can vary from patient to patient and between tumor types [10],
predictive biomarkers may identify patients more likely to benefit from such therapies [11]. Tumor PD-L1 expression
has been established as a biomarker for patient selection for monotherapy with the anti-PD-1 monoclonal antibody
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pembrolizumab in multiple tumor types including advanced non-small-cell lung cancer (NSCLC), melanoma,
cervical cancer, gastric cancer, head and neck squamous cell cancer and esophageal cancer [2,12–18], and MSI-H has
been established as a tumor-agnostic biomarker for pembrolizumab monotherapy [2,19–21].
Activity of immune checkpoint inhibitors against uncommon solid tumor types is being evaluated in clinical
trials. For example, KEYNOTE-158 is a single-arm, phase II, multicohort study investigating the antitumor activity
and safety of pembrolizumab in ten advanced solid tumor types, regardless of biomarker status. Preliminary results
from several of these cohorts demonstrated antitumor activity and durable responses, including in patients with
PD-L1-positive or MSI-H tumors [17,22–25]. However, there are limited data on either the prevalence of PD-L1
positivity or MSI-H status in these tumor types. In addition, the potential relationships between these biomarkers
and clinical outcomes among patients receiving standard of care (SOC) treatment (which for some patients included
best supportive care) need to be assessed to provide context for interpreting results from studies without a comparator
arm. We conducted a retrospective, observational study to evaluate the real-world prevalence of PD-L1 positivity
(evaluated by immunohistochemistry [IHC]) and MSI-H status (evaluated by PCR or IHC) and the association of
these biomarkers with overall survival (OS) among immunotherapy-naive patients who received SOC therapy in
the same ten advanced tumor types included in the KEYNOTE-158 phase II multicohort study of pembrolizumab
monotherapy.
Methods
Study design & patients
Eligible patients were identified within the Aarhus University (Denmark) pathology network using the Danish
Pathology Register for tissue and the associated clinical database. The Danish Pathology Register is a nationwide
data bank containing all clinical histology and cytology reports conducted by the country’s pathology depart-
ments [26]. Additional patient information was obtained through the Danish National Patient Registry. Eligible
patients were ≥18 years of age at the time of diagnosis and had tissue samples collected between 1 January 2010 and
31 December 2015. However, because there were few cases with sufficient tissue availability for neuroen-
docrine tumors, biliary carcinoma and cervical carcinoma, allowance was granted to expand the study period to
1 January 2001 to 31 December 2015 for these three tumor types. Patients were included if they had a histologically
or cytologically documented advanced (unresectable and/or metastatic) solid tumor of the following types: anal
carcinoma, biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic cholangiocarcinoma]
excluding Ampulla of Vater cancers), neuroendocrine tumors (including well-differentiated or moderately differen-
tiated tumors of the lung, appendix, small intestine, colon, rectum or pancreas), endometrial carcinoma (excluding
sarcomas and mesenchymal tumors), cervical carcinoma (including squamous cell carcinoma and adenocarci-
noma), vulvar carcinoma, small-cell lung carcinoma (SCLC), mesothelioma, thyroid carcinoma and salivary gland
carcinomas (excluding sarcomas and mesenchymal tumors). Patients were treated with SOC therapy, which was
anticipated to comprise cytotoxic chemotherapy for most patients and for patients with poor performance status
or no further documented treatment options, best supportive care. Given the study enrollment dates, patients were
not anticipated to have received immunotherapy. Each formalin-fixed paraffin-embedded tissue was to produce up
to 16 slides for biomarker analysis. Patients were excluded if they had an additional malignancy within 2 years of
the cancer diagnoses under study. Between 40 and 45 patients were included for each of the cancer types of interest,
with a preference for patients with samples collected most recently. This target was not met for neuroendocrine
tumors (n = 30) or biliary carcinoma (n = 16) because of the availability of tissue samples of these cancers.
Biomarker assessments
For biomarker analysis, slides were prepared from freshly cut samples at Aarhus University Hospital (Denmark)
and then centrally evaluated by NeoGenomics Laboratories Inc. (Fort Myers, FL, USA). PD-L1 expression was
assessed utilizing the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies, CA, USA); samples with a combined
positive score (CPS) ≥1 were considered positive consistent with the prespecified PD-L1 CPS ≥1 cutoff point in
the KEYNOTE-158 study. The CPS was calculated by summing the number of PD-L1-stained cells (tumor cells,
lymphocytes, macrophages) and dividing the result by the total number of viable tumor cells, multiplied by 100 [27].
MSI was measured by PCR using the Promega MSI Analysis system version 1.2 (Promega Corporation, WI, USA)
at one central laboratory (Almac Diagnostic Services, Craigavon, Northern Ireland). Samples were considered
MSI-H if the PCR assay showed ≥2 of five MSI loci that differed in size from corresponding normal loci.
For samples that could not be tested using the PCR assay, either because of the small amount of tissue or
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unavailability of a ‘normal’ control, IHC was performed at a single laboratory (Aarhus University Hospital). The
sample was considered MSI-H if the IHC assay demonstrated loss of ≥1 of the proteins MLH1 (clone ES05, Dako,
CA, USA), MSH2 (FE11, Dako), MSH6 (EP49, Dako) or PMS2 (EP51, Dako) (i.e., dMMR). PCR and IHC
are commonly used in combination for MSI testing, and there is a very high correlation between PCR and IHC
results [28].
Statistical analysis
The frequency of biomarker expression (PD-L1 or MSI-H) was estimated with corresponding 95% CIs. OS analysis
following first-line SOC included all eligible patients; an additional OS analysis was performed in patients who
received only second-line therapy. OS (defined as the time from diagnosis [for first-line treatment], or from the
start of second-line treatment, to death due to any cause) was evaluated by the Kaplan–Meier method, stratified
by biomarker status. Log-rank tests were used to assess between-group differences in survival with a significance
level set at 0.05. Cox proportional hazards models, both unadjusted and adjusted for age, sex, sample year, and
Eastern Cooperative Oncology Group Performance Status (ECOG PS), were used to estimate hazard ratios (HR)
and their associated 95% CIs. In addition to the primary analysis of outcomes evaluating a PD-L1 CPS ≥1 cutoff,
a sensitivity analysis evaluating a PD-L1 CPS ≥10 cutoff was also performed.
Results
Patients
A total of 426 patients were identified from the Aarhus University pathology network and met eligibility criteria
across the ten prespecified tumor types. Of these, 22 had insufficient or inadequate samples. For most of the
tumor types, there were 40–49 samples, with the exception of neuroendocrine tumors (n = 30) and biliary cancers
(n = 16). Baseline demographics and clinical characteristics are described in Table 1. Baseline characteristics
among this population of patients who received SOC therapy between 2010 and 2015 (not anticipated to include
immunotherapy) were generally similar between the PD-L1-positive and PD-L1-negative populations. Median age
(PD-L1-positive, 67.0 years; PD-L1-negative, 62.0 years), proportion of female patients (PD-L1-positive, 65%;
PD-L1-negative, 62%) and proportion of patients with ECOG PS of 0 (PD-L1-positive, 38%; PD-L1-negative,
37%) were similar between the groups. Among the 404 patients with adequate tissue samples evaluated for PD-L1
expression, six were excluded owing to assay failure and an additional 13 patients were excluded from OS analysis
owing to missing critical clinical data; 385 patients were included in the OS analysis (Figure 1).
Of the 426 patients meeting eligibility criteria, 51 were excluded from MSI evaluation due to insufficient
or inadequate sample. 284 samples were submitted for MSI PCR testing; 13 samples were excluded because
of assay failure. The remaining 91 samples, which did not contain sufficient ‘normal tissue’ for PCR using
the Promega MSI Analysis system, were tested with an IHC-based assay targeting the proteins involved in the
mismatch repair system. Of the 91 samples processed at the study site for dMMR IHC testing, two were ex-
cluded because of assay failure. Overall, 360 patient samples had a valid test for mismatch repair deficiency
(MSI assay, n = 271 and dMMR IHC, n = 89) (Figure 1).
Prevalence of PD-L1 expression
Among the 398 patients with valid PD-L1 IHC results, 242 (61%; 95% CI: 56–66%) had PD-L1 CPS ≥1.
PD-L1 expression was detected in all tumor types evaluated. With the exception of small-cell lung cancer
(42%; 95% CI: 28–58%) and neuroendocrine tumors (13%; 95% CI: 4–31%; Figure 2), the prevalence of PD-L1
expression (i.e., CPS ≥1) in each of the tumor types evaluated was greater than 50%. The distribution of PD-
L1 positivity was similar in the total study population and among patients who received second-line treatment
(39 and 36%, respectively).
OS & PD-L1 expression
OS after the start of first-line SOC therapy was significantly shorter in patients with PD-L1 CPS ≥1 (n = 242)
than in those with PD-L1 CPS <1 (n = 156): median OS was 23.0 months in patients with CPS ≥1 (95% CI:
18.1–37.1) and 39.7 months in patients with CPS <1 (95% CI: 23.6–73.5) with an unadjusted HR of 1.39
(95% CI: 1.07–1.81; p = 0.0136; Figure 3A). A similar outcome was observed in analyses adjusted for age, sex,
sample year and ECOG PS (HR: 1.46; 95% CI: 1.11–1.92). Because these adjustments did not meaningfully alter
the outcome and because the adjusted analyses excluded a significant proportion of patients owing to missing
future science group www.future-science.com
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Patients meeting eligibility criteria
n = 426*
Samples shipped for
MSI testing by PCR
22 excluded
22 missing clinical data
Samples shipped for
PD-L1 testing
n = 404 n = 284
51 excluded
29 insufficient sample
22 missing clinical data
Samples processed at
study site for IHC dMMR
testing
n = 91
13 excluded
because of assay
failure
6 excluded
because of assay
failure
Samples with valid
PD-L1 result
n = 398
13 excluded
because of 
missing OS data
Patients included in OS
analysis
n = 385
Samples with valid
MSI result by PCR
n = 271
Samples with valid
dMMR result
n = 89
Patients with valid
MSI result
n = 360
2 excluded
because of assay
failure
Figure 1. Patient selection and tumor sample evaluation of PD-L1 and microsatellite instability. Eligible patients
were identified within the Aarhus University pathology network using the Danish Pathology Register for tissue and
the associated clinical database. *Initial screening identified 435 patients; nine were excluded because of duplicate
records.
dMMR: Deficient mismatch repair; dMMR IHC: Immunohistochemistry deficient mismatch repair; MSI: Microsatellite
instability; OS: Overall survival.
ECOG PS data, we subsequently focused on unadjusted analyses. A similar trend was observed when the cut point
was set at PD-L1 CPS ≥10 versus CPS <10. Median OS was 32.7 months in patients with PD-L1 CPS <10
(95% CI: 21.9–40.7) and 22.5 months in patients with CPS ≥10 (95% CI: 14.7–49.2), with an unadjusted HR
of 1.26 (95% CI: 0.98–1.75; p = 0.1158; Figure 3B). Similar findings were observed with PD-L1 CPS ≥50 as the
cutoff. The HR for OS was 1.29 (95% CI: 0.81–2.04) for CPS ≥50 versus CPS <50. However, there were only
27 patients with PD-L1 CPS ≥50.
OS after initiation of second-line (nonimmunotherapy) treatment (n = 91) did not differ significantly by PD-L1
status (unadjusted HR: 1.07 [95% CI: 0.66–1.75]; p = 0.77). Median OS was 10.8 months in patients with a
CPS <1 (n = 33; 95% CI: 6.7–24.3) and 11.5 months in patients with CPS ≥1 (n = 58; 95% CI: 9.2–15.7;
Figure 3C).
Similar findings were also observed in a sensitivity analysis that defined OS from the time of second-line
treatment initiation to death from any cause (p = 0.23). Median OS was 10.8 months among patients with a CPS
<10 (n = 72; 95% CI: 7.9–15.1) and 13.4 months in those with CPS ≥10 (n = 19; 95% CI: 6.1–44.0), resulting
in an unadjusted HR of 0.92 (95% CI: 0.25–1.63; p = 0.77).
Prevalence of MSI-H
MSI-H was detected in only eight (2.2%; 95% CI: 0.9–4.3%) of the 360 evaluable tumor samples. All MSI-H
tumors identified were in patients with gynecologic cancers, including endometrial carcinoma (7/49 [14.3%;
95% CI: 6.0–27.3%]) and cervical carcinoma (1/44 [2.3%; 95% CI: 0.1–12.1%]; Figure 2). Among the eight
future science group www.future-science.com
Research Article Steiniche, Ladekarl, Georgsen et al.
0
20
30
40
50
70
80
90
P
D
-L
1 
(C
P
S
 ≥
 1
) 
p
re
va
le
n
ce
 (
%
)
Neuroendo-
crine tumors
n = 30
100
60
10
Small-cell
lung cancer
n = 45
Biliary
adeno-
carcinoma
n = 16
Thyroid
carcinoma
n = 46
Cervical
carcinoma
n = 44
Salivary
glands
n = 46
Endometrial
carcinoma
n = 49
Mesothelioma
n = 44
Anal
carcinoma
n = 40
Vulvar
carcinoma
n = 44
86.0 82.5 80.5
69.4
61.4
54.5 50.0
50.0 42.2
13.3
Figure 2. Prevalence of PD-L1 combined positive score ≥1 by tumor type. Analysis included all tumor types. Evaluation of PD-L1 CPS in
tissue samples was performed using the PD-L1 IHC 22C3 pharmDx assay (Agilent, CA, USA) and samples with a CPS ≥1 were considered
positive.
IHC: Immunohistochemistry; PD-L1 CPS: PD-L1 combined positive score.
patients assessed as MSI-H, seven (87.5%) were also PD-L1 positive. Clinical outcomes by MSI-H status were not
evaluated due to the low prevalence of MSI-H tumors.
Discussion
This retrospective longitudinal study evaluated the prevalence of PD-L1 expression (as assessed by CPS ≥1) and
identified an association of tumor PD-L1 (CPS ≥1) expression with shorter OS in response to first-line SOC
therapy in patients with ten prespecified solid tumor types. Because patients from 2010 to 2015 were included,
patients were anticipated to be immunotherapy-naive. Expression of PD-L1 by IHC was detected in 61% of
evaluable tumor samples overall; the prevalence varied by tumor type (range: 13–87%). Notably, PD-L1 expression
was detected in all evaluated tumor types, with prevalence ranging from 13% (neuroendocrine tumors) to 86%
(vulvar carcinoma). PD-L1 CPS ≥1 was associated with shorter OS after first-line treatment compared with PD-L1
CPS <1, whereas PD-L1 CPS ≥10 was not associated with shorter OS after first-line treatment. There was no
significant difference in OS by PD-L1 status after second-line treatment. Overall, these results demonstrate that
PD-L1 is commonly expressed in a variety of advanced solid tumors, with a prevalence of ≥50% in eight of the ten
tumor types evaluated, and that PD-L1 expression is not associated with improvement in OS after either first-line
or second-line SOC therapy.
Evidence from prospective clinical studies of pembrolizumab monotherapy has indicated an association between
higher tumor PD-L1 expression and improved clinical outcomes [12,29,30]. However, there are limited data evaluating
any potential prognostic value of tumor PD-L1 expression [30] in patients receiving SOC therapy (i.e., nonim-
munotherapeutic treatments, particularly those with less frequently occurring tumor types such as those included
in this study). Results from the current retrospective longitudinal study suggest that PD-L1 expression is associated
with shorter OS after first-line SOC therapy (nonimmunotherapy) across a range of tumors (unadjusted HR: 1.39
[95% CI: 1.07–1.81]; p = 0.0136). Consistent with our findings, previous studies have identified an association
of PD-L1 expression with shorter OS in patients with malignant salivary gland tumor [31], malignant pleural
mesothelioma [32], NSCLC [30,33] and pancreatic cancer [30,34]. In contrast, other studies have reported that PD-L1
expression was associated with longer OS in patients with NSCLC [35] and SCLC [36]. Furthermore, other studies
have reported no prognostic value for PD-L1 expression in patients with cervical cancer [37], SCLC [33] and anal
squamous cell carcinoma [38]. A number of factors may have contributed to these differences, including but not
limited to differences in PD-L1 assessment techniques and small-sample sizes. Additionally, it is important to note
in a number of the aforementioned previous reports, it was not clearly defined whether patients had received or
were receiving treatment, and this may have confounded assessment of the prognostic value of PD-L1 expression.
Furthermore, because the tumor microenvironment is made up of heterogeneous cell populations, other biologic
Future Sci. OA (2020) 6(8) future science group
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Figure 3. Overall survival by PD-L1 combined positive score. Kaplan–Meier estimates of overall survival among
patients with (A) PD-L1 CPS ≥1 and <1 in the overall study population after first-line treatment,
(B) PD-L1 CPS ≥10 and <10 in the overall study population after first-line treatment, and (C) PD-L1 CPS ≥1 and <1 in
the overall study population after second-line treatment.
aAdjusted HR is based on Cox proportional hazard models that included year (derived from sample collection date),
age, sex, and ECOG. Missing ECOG PS was treated as a separate category and included in the model for adjustment.
Overall survival was defined as the time from diagnosis to death from any cause.
CPS: Combined positive score; ECOG PS: Eastern Cooperative Oncology Group performance status; HR: Hazard ratio;
Mo: Months; SOC: Standard of care.
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processes (potentially including but not limited to: secretion of growth factors and chemokines, production of
blood vessels, myeloid-derived suppressor cell production of nitric oxide synthase and reactive oxygen species and
infiltration of T-regulatory cells) may influence the effectiveness of PD-L1 as a biomarker among different tumor
types [39]. At present, it is uncertain how such processes might influence the prognostic value of PD-L1.
The findings from the current study may aid in the interpretation of single-arm studies where it can be difficult to
evaluate whether a biomarker is truly predictive of treatment outcome or is prognostic (i.e., indicative of outcome
irrespective of treatment). Our results suggest that tumor PD-L1 CPS is not a positive prognostic factor for OS in
patients with ten uncommon tumor types who received SOC therapy. As such, when evaluating single-arm trial
data for checkpoint inhibitors (including pembrolizumab studies such as KEYNOTE-158), it is likely that any
association between tumor PD-L1 CPS and a favorable outcome is representative of predictive value rather than of
selection of patients with improved prognosis.
In our study, the overall prevalence of patients with MSI-H tumors was only 2.2%, with seven out of eight
MSI-H tumors occurring in the endometrial cancer group in which the prevalence of MSI-H was 14.3%
(95% CI: 6.0–27.3%). These findings suggest lower prevalence of MSI-H where earlier studies have reported
MSI-H frequencies between 28.3 and 31.37% in endometrial cancer [40,41]. This may potentially be explained
by better prognosis for patients with MSI-H who would be underrepresented in this study, which focuses on
patients with advanced/incurable disease. The KEYNOTE-158 study previously demonstrated the clinical benefit
of pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal
cancer, providing further evidence to support MSI-H as a predictive biomarker for response to anti-PD-1 therapy [25].
This study is one of the largest to investigate associations between PD-L1 and OS in patients with uncommon
cancers receiving SOC therapy. All biomarker assessments were conducted in a standardized fashion within a single
central laboratory to minimize variability in evaluation. Additionally, patients were identified through a nationally
representative network in Denmark instead of a single center. However, despite the large overall sample size, the
numbers of patients in each individual cancer type did not allow further by-cancer-type analyses. An important
confounding factor in our retrospective analyses was that we compared OS in a mixed and heterogeneous population
of patients with different proportions of tumor types and baseline characteristics between the two groups.
Conclusions
PD-L1 is commonly expressed in a range of advanced tumors, and we demonstrate an association of tumor PD-L1
expression with shorter OS in patients after first-line SOC therapy.
Future perspective
Results from this study may be used to aid in interpretation of clinical trials evaluating PD-L1 as a predictive
biomarker for pembrolizumab therapy. Prospective studies may further delineate the prognostic value of PD-L1
expression and MSI-H in the tumor types evaluated.
Summary points
• This is one of the largest studies to investigate associations between PD-L1 expression (by combined positive
score) and overall survival in patients with uncommon cancers (anal, cervical, endometrial, salivary gland,
small-cell lung, thyroid and vulvar carcinoma, biliary adenocarcinoma, mesothelioma and neuroendocrine
tumors) receiving standard-of-care therapy, including best supportive care.
• PD-L1 and high levels of microsatellite instability are established biomarkers for PD-1/PD-L1 immune checkpoint
inhibitors, but current evidence for the prognostic value of PD-L1 is limited.
• PD-L1 was expressed in all ten advanced uncommon cancers with an overall prevalence of 61%.
• We report an association of tumor PD-L1 expression (combined positive score ≥1) with shorter overall survival in
patients after first-line standard-of-care therapy, including best supportive care.
• There was no association between tumor PD-L1 expression and overall survival after second-line therapy.
• High level of microsatellite instability expression was identified infrequently and only in endometrial and cervical
carcinomas.
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